GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities. The FTSE 100 index rose 12.01 ...

GSK’s 6% results-day share price advance is the standout performance in an otherwise subdued FTSE 100 index. Miner Fresnillo ...

Strong full-year trading and an improving outlook have propelled GSK's share price higher, as Royston Wild explains.

GSK shares surge as the drugmaker raises its 2031 sales target to over £40bn, boosts dividends, and announces a £2bn share buyback plan.